Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of THDBH120 in Healthy Subjects
NCT06744868Phase 1Completed
- Sponsor
- Tonghua Dongbao
- Start
- Dec 2023
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of THDBH120 in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Tonghua Dongbao. Primary endpoint: Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s). Started Dec 2023; status: completed.
02
Drugs
THDBH120
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06744868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744868.